Patent ID: 7229775

Claim:
An immunological assay for the detection and/or quantification of an analyte of human MDA-modified LDL (malondialdehyde-modified low density lipoprotein) and human OxLDL (oxidized low density lipoprotein) in a sample derived from the blood or tissue of a human being, said assay comprising: (a) contacting the analyte in the sample with (i) monoclonal antibody mAb-4E6 produced by hybridoma Hyb4E6, which was deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) under deposit accession number LMBP 1660 CB on Apr. 24, 1997, and (ii) optionally monoclonal antibody mAb-8A2 produced by hybridoma Hyb8A2, which was deposited at the BCCM under deposit accession number LMBP 1661 CB on Apr. 24, 1997; and (b) thereafter visualizing and/or quantifying a binding reaction between the one or two antibodies and the analyte present in the sample; wherein the MDA-modified LDL and OxLDL contain at least 60 substituted lysine moieties per apo B-100 (apolipoprotein B-100) moiety.